pSivida Corp. (NASDAQ:PSDV) issued its quarterly earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15), Bloomberg Earnings reports. pSivida Corp. had a negative net margin of 245.19% and a negative return on equity of 134.34%.

pSivida Corp. (NASDAQ PSDV) traded down $0.10 during mid-day trading on Tuesday, reaching $1.16. 1,096,921 shares of the company traded hands, compared to its average volume of 749,656. pSivida Corp. has a 1-year low of $1.03 and a 1-year high of $2.45.

ILLEGAL ACTIVITY NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/07/psivida-corp-psdv-releases-earnings-results-meets-estimates.html.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of pSivida Corp. in a report on Wednesday, September 27th. Five investment analysts have rated the stock with a buy rating, pSivida Corp. presently has a consensus rating of “Buy” and a consensus target price of $8.60.

pSivida Corp. Company Profile

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Earnings History for pSivida Corp. (NASDAQ:PSDV)

Receive News & Stock Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related stocks with our FREE daily email newsletter.